{"organizations": [], "uuid": "47f1684e6754e9f9a5a5a10decbf7ddbc2248aa7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/21/globe-newswire-fibrogen-to-report-fourth-quarter-and-full-year-2017-financial-results-on-tuesday-february-27-2018.html", "country": "US", "domain_rank": 767, "title": "FibroGen to Report Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 27, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.004, "site_type": "news", "published": "2018-02-21T15:00:00.000+02:00", "replies_count": 0, "uuid": "47f1684e6754e9f9a5a5a10decbf7ddbc2248aa7"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/21/globe-newswire-fibrogen-to-report-fourth-quarter-and-full-year-2017-financial-results-on-tuesday-february-27-2018.html", "ord_in_thread": 0, "title": "FibroGen to Report Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 27, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "san francisco", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "san fra", "sentiment": "none"}], "organizations": [{"name": "globe newswire", "sentiment": "negative"}, {"name": "fibrogen", "sentiment": "negative"}, {"name": "fibrogen fibrogen, inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN FRANCISCO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report fourth quarter and full year 2017 financial results on Tuesday, February 27, 2018 after market close, and will host a conference call to discuss financial results and provide a business update at 5:00 p.m. ET (2:00 p.m. PT).\nConference Call and Audio Webcast\nInterested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com . It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 46307822#.\nDial-In Information\nLive (U.S./Canada): (888) 771-4371\nLive (International): (847) 585-4405\nConfirmation number: 46307822\nAbout FibroGen\nFibroGen, Inc., headquartered in San Francisco, CA with subsidiary offices in Beijing and Shanghai, PRC, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology and clinical development to advance innovative medicines for the treatment of anemia, and fibrotic disease and cancer. Roxadustat, the companyâ€™s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD) with the exception of China, where a new drug application is currently under review by the CFDA for regulatory approval. Roxadustat is also entering Phase 3 development for anemia in myelodysplastic syndromes (MDS). Pamrevlumab, a fully-human monoclonal anti-CTGF antibody, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com .\nContact\nKaren L. Bergman\nVice President, Investor Relations and\nCorporate Communications\nFibroGen, Inc.\nkbergman@fibrogen.com\n(415) 978-1433\nSource:FibroGen, Inc", "external_links": ["https://www.globenewswire.com/Tracker?data=d3-p_VOx2brkKig7R8ykwVvN7ASQUkttGwWO4BnAlrBlKxThTWZGR1FLb4CfKuHGt5dB3mLRnrKHFwnWYVrCcaT4x9_Yd8QzAc-1DSiTyZo-bIi04Yyp6ql-N9FO6gjNqyyr0Dv5ActQbajuz_RPxMKsxiaoJibHXWQAxH-LhxqgZ0-OusJ1Q3aA5m-wd1HmuZYUbvlxZyKkAhpBq-HVPR5AdIwRegISe1UuQU4jhG3_xUxlWBCNg4D_hDjWkmdAjharC3g4VwJWb_KTMAuNfBU6dIVyVqjuVfgXAhyDs-QyKwDcD_jrMt_IrWLvAf8OjC6E-fyjcbvmhLkCM2x2Cr-LzPCy-ZXaBc2pAJvqsEZ85KUX-HlKC6G0Dwsvs4XkctBpLQpJJDklsJsehbRWnIIAUg93O7aWIwQ_bonA6gJp4gwJjK31o7v4z44KNndhk2pzFHsd8Mmzmue6M-TB0iKNZD0XsIUFuBhozUW", "https://www.globenewswire.com/Tracker?data=15LHhC18hsg-eW-L4BmH3cilE1KcqOqgVcf9m_zVaOdaU6ZE6RC-1mg0hB3G2s0pIZwaA6bjZSzeUvRvIn9ONG9r1phIgLJ7R_ccf7sIQKo=", "https://www.globenewswire.com/Tracker?data=d3-p_VOx2brkKig7R8ykwaM9qhjIi3BU8Nr_W_0RbQ50U5FDd2GinjlmeX1F7yzYBquO9kTy8AItNDlHPd8MmQ==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/46ba2e82-b8e4-48b1-b377-25777182a7d2"], "published": "2018-02-21T15:00:00.000+02:00", "crawled": "2018-02-21T15:47:38.000+02:00", "highlightTitle": ""}